EMA/HMA - Tackling vulnerabilities in the supply chain of radiopharmaceuticals in the EU

16th April 2025

EMA/HMA - Tackling vulnerabilities in the supply chain of radiopharmaceuticals in the EU

EMA and the Heads of Medicines Agencies (HMA), through the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG), have issued recommendations to address vulnerabilities in the supply chain of radiopharmaceuticals. These types of medicines contain radioactive forms of chemical elements called radioisotopes and are used to diagnose or treat medical conditions such as cancer. Their use is steadily increasing, while manufacturing capacity in Europe is limited. This has led to occasional shortages in different Member States.

Read More

Back to Recent News